Electromed (ELMD)
(Delayed Data from AMEX)
$22.67 USD
+0.36 (1.61%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $22.61 -0.06 (-0.26%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.67 USD
+0.36 (1.61%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $22.61 -0.06 (-0.26%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. (ELMD) Reports Next Week: What Awaits?
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed, Inc. (ELMD) Q4 Earnings Meet Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 0.00% and 1.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. (ELMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Electromed, Inc. (ELMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).
New Strong Sell Stocks for June 3rd
by Zacks Equity Research
ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021
New Strong Sell Stocks for May 13th
by Zacks Equity Research
PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021
Earnings Preview: Electromed, Inc. (ELMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of 225.00% and 15.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Electromed, Inc. (ELMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Electromed Enters Oversold Territory
by Zacks Equity Research
Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Electromed Enters Oversold Territory
by Zacks Equity Research
Electromed has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus
by Debanjana Dey
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital
by Zacks Equity Research
Zacks.com featured highlights include: Vista Outdoor, 21Vianet, Electromed and GAIN Capital
4 Breakout Stocks for Explosive Returns
by Nitish Marwah
In order to select the right breakout stock one has to first calculate its support and resistance level.
5 Themes (& Picks) for Coronavirus Investing
by Sejuti Banerjea
Coronavirus is going to be around for a while, so let's use it to define our investment strategies.
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
by Zacks Equity Research
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
5 Stocks With Recent Price Strength Amid Coronavirus Logjam
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now
by Benjamin Rains
DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...
5 Top Low-Beta Stocks Surged in March Defying Coronavirus
by Nalak Das
The global financial markets are currently witnessing one of the worst periods since the Great Depression due to the coronavirus-led crisis.